Parkinson's disease

Neuroscience

Sleep disorder

Central nervous system disease

Ophthalmology

Operating system

Clinical neurology

Psychiatry

Computer science

REM sleep behavior disorder

Anesthesia

Eye movement

Placebo

Sleep (system call)

Alternative medicine

Bedtime

Psychology

Neurological disorder

Rapid eye movement sleep

Insomnia

Physical therapy

Internal medicine

Melatonin

Medicine

Physical medicine and rehabilitation

Disease

Randomized controlled trial

Pathology

Movement Disorders

Melatonin may reduce REM-sleep behavior disorder (RBD) symptoms in Parkinson's disease (PD), though robust clinical trials are lacking.To assess the efficacy of prolonged-release (PR) melatonin for RBD in PD.Randomized, double-blind, placebo-controlled, parallel-group trial with an 8-week intervention and 4-week observation pre- and postintervention (ACTRN12613000648729). Thirty PD patients with rapid eye movement sleep behavior disorder were randomized to 4 mg of prolonged-release melatonin (Circadin) or matched placebo, ingested orally once-daily before bedtime. Primary outcome was the aggregate of rapid eye movement sleep behavior disorder incidents averaged over weeks 5 to 8 of treatment captured by a weekly diary. Data were included in a mixed-model analysis of variance (n = 15 per group).No differences between groups at the primary endpoint (3.4 events/week melatonin vs. 3.6 placebo; difference, 0.2; 95% confidence interval = -3.2 to 3.6; P = 0.92). Adverse events included mild headaches, fatigue, and morning sleepiness (n = 4 melatonin; n = 5 placebo).Prolonged-release melatonin 4 mg did not reduce rapid eye movement sleep behavior disorder in PD. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson's disease: A Randomised Controlled Trial